CardiovascularTOPICALGeneric

MYCOSTATIN

NYSTATIN

Standard Dose

100,000 UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Max Dose

Refer to approved labeling

Primary Use

Marketing status: Discontinued

Summary

Approval overview MYCOSTATIN is listed in Drugs@FDA under application 060578 (ANDA).

Marketing status: Discontinued Active ingredient NYSTATIN Form and strength POWDER;TOPICAL - 100,000 UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor DELCOR ASSET CORP Submission history Latest submission status date: 1998-09-17 00:00:00.

Structured Monograph

Clinical summary

Approval overview MYCOSTATIN is listed in Drugs@FDA under application 060578 (ANDA). Marketing status: Discontinued Active ingredient NYSTATIN Form and strength POWDER;TOPICAL - 100,000 UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor DELCOR ASSET CORP Submission history Latest submission status date: 1998-09-17 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Discontinued

Interaction Notes

No interaction notes stored yet.